^
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive
:
A1
No biomarker
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive
:
A1
PDGFRA fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
ABL2 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
FGFR fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
IL7R mutation
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive
:
A2
SH2B3 alteration
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive
:
A2
CRLF2 rearrangement + JAK2 fusion
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive
:
A2
EPOR rearrangement
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive
:
A2
ABL1 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
JAK2 fusion
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive
:
A2
PDGFRB fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cytarabine + cyclophosphamide oral + vincristine + methotrexate + pegaspargase
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
vincristine + dexamethasone + mitoxantrone + pegaspargase
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide oral + etoposide oral + nelarabine
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
imatinib
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide oral + etoposide oral + clofarabine
Sensitive
:
A2
BCR-ABL1 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
bortezomib
Sensitive
:
A2
KRAS mutation
Childhood B Acute Lymphoblastic Leukemia
GS-9973
Resistant
:
C3
NRAS mutation
Childhood B Acute Lymphoblastic Leukemia
GS-9973
Resistant
:
C3
CD20 expression
Childhood B Acute Lymphoblastic Leukemia
rituximab + bortezomib
Sensitive
:
C3
HER-2 expression
Childhood B Acute Lymphoblastic Leukemia
trastuzumab
Resistant
:
C3
PAX5 fusion
Childhood B Acute Lymphoblastic Leukemia
nintedanib
Sensitive
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our